This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
COPENHAGEN, Denmark, Oct. 30, 2013 (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the Company will present at the Credit Suisse 2013 Healthcare Conference in Scottsdale, Arizona, USA and at the Jefferies 2013 London Healthcare Conference, UK.
Flemming Pedersen, CFO and EVP, will provide an overview of the Company and its key programmes at:
Credit Suisse 2013 Healthcare Conference at The Phoenix, Scottsdale, Arizona, USA on Wednesday, 13 November at 3.30 PM Mountain Standard Time
Jens Bager, President and CEO, will provide an overview of the Company and its key programmes at:
Jefferies 2013 London Healthcare Conference at The Waldorf Hilton, London, UK on Wednesday, 20 November at 2.20 PM Greenwich Mean Time
Jens Bager President and CEO
For further information please contact:
Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Janet Dally, tel. +1 609-466-0466
Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143
About ALKALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is the world leader in allergy immunotherapy - a unique treatment of the underlying cause of allergy. The company has approximately 1,800 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Merck (MSD outside the USA and Canada) and Torii to commercialise allergy immunotherapy tablets in North America and Japan, respectively. The company is headquartered in Hoersholm, Denmark, and listed on NASDAQ OMX Copenhagen. Find more information at www.alk.net.
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.